The promise of futility trials in neurological diseases

Nature Reviews Neurology

Volumn 11, Issue 5, 2015, Pages 300-305

  Koch, Marcus W ^a   Korngut, Lawrence ^a   Patry, David G ^a   Agha Khani, Yahya ^a   White, Christopher ^a   Sarna, Justyna R ^a   Yeung, Michael ^a   Yong, V Wee ^a   Heng, Daniel Y C ^b   Cutter, Gary ^c   Metz, Luanne ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DISUFENTON SODIUM; RILUZOLE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL STUDY; CREUTZFELDT JAKOB DISEASE; EPILEPSY; EXPANDED DISABILITY STATUS SCALE; FUTILITY TRIAL; HUMAN; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; NEUROLOGIC DISEASE; NEUROLOGIC DISEASE ASSESSMENT; NULL HYPOTHESIS; ONCOLOGY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; SOFT TISSUE SARCOMA; SPINAL MUSCULAR ATROPHY; BIOLOGICAL MODEL; COGNITION DISORDERS; NERVOUS SYSTEM DISEASES; PHASE 2 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE II AS TOPIC; COGNITION DISORDERS; HUMANS; MEDICAL FUTILITY; MODELS, BIOLOGICAL; NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE;

EID: 84929281003     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.34     Document Type: Review

References (68)

1. Van Glabbeke, M. et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38, 543-549 (2002).
2. A'Hern, R. P. Sample size tables for exact single-stage phase II designs. Stat. Med. 20, 859-866 (2001).
3. Gehan, E. A. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chronic Dis. 13, 346-353 (1961).
4. Fleming, T. R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 38, 143-151 (1982).
5. Simon, R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10, 1-10 (1989).
6. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66, 664-671 (2006).
7. Fahn, S. et al. in Recent Developments in Parkinson's Disease Vol. 2 (eds Fahn, S. et al.) 153-163 (Macmillan Healthcare Information, 1987).
8. [No authors listed] DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch. Neurol. 46, 1052-1060 (1989).
9. Elm, J. J. et al. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann. Neurol. 57, 197-203 (2005).
10. Tilley, B. C. et al. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology 66, 628-633 (2006).
11. D'Agostino, R., Chase, W. & Belanger, A. The appropriateness of some common procedures for testing the equality of two independent binomial populations. The American Statistician 42, 198-202 (1988).
12. Schwid, S. R. & Cutter, G. R. Futility studies: spending a little to save a lot. Neurology 66, 626-627 (2006).
13. Tabrizi, S. J. et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 11, 42-53 (2012).
14. Tabrizi, S. J. et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 12, 637-649 (2013).
15. Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov. Disord. 28, 1407-1415 (2013).
16. Walker, F. O. Huntington's disease. Lancet 369, 218-228 (2007).
17. Schrag, A., Ben-Shlomo, Y. & Quinn, N. P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354, 1771-1775 (1999).
18. O'Collins, V. E. et al. 1,026 experimental treatments in acute stroke. Ann. Neurol. 59, 467-477 (2006).
19. Diener, H. C. et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 39, 1751-1758 (2008).
20. Green, A. R. & Shuaib, A. Therapeutic strategies for the treatment of stroke. Drug Discov. Today 11, 681-693 (2006).
21. Sacchetti, M. L. Is it time to definitely abandon neuroprotection in acute ischemic stroke? Stroke 39, 1659-1660 (2008).
22. Neuhaus, A. A. et al. Importance of preclinical research in the development of neuroprotective strategies for ischemic stroke. JAMA Neurol. 71, 634-639 (2014).
23. Tymianski, M. Novel approaches to neuroprotection trials in acute ischemic stroke. Stroke 44, 2942-2950 (2013).
24. Brott, T. et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20, 864-870 (1989).
25. Van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J. & van Gijn, J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19, 604-607 (1988).
26. Mahoney, F. I. & Barthel, D. W. Functional evaluation: the Barthel Index. Md State Med. J. 14, 61-65 (1965).
27. Tilley, B. C. & Galpern, W. R. Screening potential therapies: lessons learned from new paradigms used in Parkinson disease. Stroke 38, 800-803 (2007).
28. [No authors listed] Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581-1587 (1995).
29. Palesch, Y. Y., Tilley, B. C., Sackett, D. L., Johnston, K. C. & Woolson, R. Applying a phase II futility study design to therapeutic stroke trials. Stroke 36, 2410-2414 (2005).
30. Kiernan, M. C. et al. Amyotrophic lateral sclerosis. Lancet 377, 942-955 (2011).
31. Bensimon, G., Lacomblez, L. & Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 330, 585-591 (1994).
32. Cudkowicz, M. E. et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 12, 1059-1067 (2013).
33. UKMND-LiCALS Study Group et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 12, 339-345 (2013).
34. Gordon, P. H. et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6, 1045-1053 (2007).
35. Palesch, Y. Y. & Tilley, B. C. An efficient multi-stage, single-arm Phase II futility design for ALS. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5 (Suppl. 1), 55-56 (2004).
36. Zerres, K. & Rudnik-Schöneborn, S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch. Neurol. 52, 518-523 (1995).
37. Finkel, R. S. et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83, 810-817 (2014).
38. Markowitz, J. A., Singh, P. & Darras, B. T. Spinal muscular atrophy: a clinical and research update. Pediatr. Neurol. 46, 1-12 (2012).
39. Hirtz, D. et al. Challenges and opportunities in clinical trials for spinal muscular atrophy. Neurology 65, 1352-1357 (2005).
40. Swoboda, K. J. et al. Perspectives on clinical trials in spinal muscular atrophy. J. Child Neurol. 22, 957-966 (2007).
41. Mercuri, E., Bertini, E. & Iannaccone, S. T. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 11, 443-452 (2012).
42. Weinshenker, B. G. et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112, 133-146 (1989).
43. Koch, M. W., Cutter, G., Stys, P. K., Yong, V. W. & Metz, L. M. Treatment trials in progressive MS-current challenges and future directions. Nat. Rev. Neurol. 9, 496-503 (2013).
44. Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444-1452 (1983).
45. Ontaneda, D. et al. Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures. Mult. Scler. 18, 1074-1080 (2012).
46. Cutter, G. R. et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122, 871-882 (1999).
47. Bosma, L. V. et al. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult. Scler. 15, 715-720 (2009).
48. Wolinsky, J. S. et al. Glatiramer acetate in primary progressive multiple sclerosis: resultsof a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol. 61, 14-24 (2007).
49. Cohen, J. A. et al. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 59, 679-687 (2002).
50. Freedman, M. S. et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 77, 1551-1560 (2011).
51. Koch, M., Uyttenboogaart, M., van Harten, A., Heerings, M. & De Keyser, J. Fatigue, depression and progression in multiple sclerosis. Mult. Scler. 14, 815-822 (2008).
52. Koch, M. W. et al. Depression in multiple sclerosis: a long-term longitudinal study. Mult. Scler. 21, 76-82 (2015).
53. Marson, A. et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 365, 2007-2013 (2005).
54. Marson, A. G. et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369, 1000-1015 (2007).
55. Marson, A. G. et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369, 1016-1026 (2007).
56. Kwan, P., Schachter, S. C. & Brodie, M. J. Drug-resistant epilepsy. N. Engl. J. Med. 365, 919-926 (2011).
57. Arzimanoglou, A. et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 8, 82-93 (2009).
58. Wheless, J. W. & Constantinou, J. E. Lennox-Gastaut syndrome. Pediatr. Neurol. 17, 203-211 (1997).
59. Chiron, C. Current therapeutic procedures in Dravet syndrome. Dev. Med. Child Neurol. 53 (Suppl. 2), 16-18 (2011).
60. Mikati, M. A. & Shamseddine, A. N. Management of Landau-Kleffner syndrome. Paediatr. Drugs 7, 377-389 (2005).
61. [No authors listed] Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 39, 799-803 (1998).
62. Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141, 1356-1364 (1984).
63. Birks, J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD005593. http://dx.doi.org/10.1002/ 14651858.CD005593.
64. Schrag, A. et al. What is the clinically relevant change on the ADAS-cog? J. Neurol. Neurosurg. Psychiatry 83, 171-173 (2012).
65. Rascovsky, K. et al. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 65, 397-403 (2005).
66. Roberson, E. D. et al. Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology 65, 719-725 (2005).
67. Haywood, A. M. Transmissible spongiform encephalopathies. N. Engl. J. Med. 337, 1821-1828 (1997).
68. Pocchiari, M. et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 127, 2348-2359 (2004).